| Literature DB >> 14700739 |
David Blum1, Marie-Christine Galas, Laetitia Cuvelier, Serge N Schiffmann.
Abstract
3-Nitropropionic acid (3NP) is a succinate dehydrogenase inhibitor allowing the generation of animal models of Huntington's disease. In the present study, we found that a 5-day continuous chronic infusion of 3NP produces loss of [3H]mazindol binding and tyrosine hydroxylase (TH) immunoreactivity in the striatal area of degeneration. This loss of dopamine terminals was not due to a loss of nigral neurons since the expression of TH as well as the number of TH-expressing neurons remained unaltered in the substantia nigra of rats treated by 3NP. This suggests that the 3NP-induced dopamine terminal loss is secondarily related to the striatal degeneration andlor to a direct effect of 3NP on striatal terminals and not to a primary effect on nigral cells.Entities:
Mesh:
Substances:
Year: 2004 PMID: 14700739 DOI: 10.1016/j.neulet.2003.10.034
Source DB: PubMed Journal: Neurosci Lett ISSN: 0304-3940 Impact factor: 3.046